 "Rusan Pharma aims to double turnover to Rs 600 cr by 2018")
With a focus on research and development (R&D), Rusan Pharma, which specialises in pain management, opioid de-addiction & anti-infectives therapies, is aiming to double its turnover to Rs 600 by 2018.
To augment its research capability, the company will invest Rs 100 crore in a R&D centre and a manufacturing unit in Kandla (Gujarat). With this fresh investment, it will focus on research and manufacture of de-addiction and pain management drugs for domestic market and export. As a part of its expansion plan, Rusan Pharma is also planning to set up a clinical research organisation.
Rusan Pharma plans to manufacture transdermal patches at Kandla. The company, which currently exports products to Europe, Russia, South Africa and South East Asia, aims to expand exports to the US and Canada.
FOR COMPLETE REPORT READ: Rusan Pharma invests Rs 100 crore in R&D, mfg unit at Kandla
To augment its research capability, the company will invest Rs 100 crore in a R&D centre and a manufacturing unit in Kandla (Gujarat). With this fresh investment, it will focus on research and manufacture of de-addiction and pain management drugs for domestic market and export. As a part of its expansion plan, Rusan Pharma is also planning to set up a clinical research organisation.
Rusan Pharma plans to manufacture transdermal patches at Kandla. The company, which currently exports products to Europe, Russia, South Africa and South East Asia, aims to expand exports to the US and Canada.
FOR COMPLETE REPORT READ: Rusan Pharma invests Rs 100 crore in R&D, mfg unit at Kandla